Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 6/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | GSK3B | P49841 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | EP300 | Q09472 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | BUB1 | O43683 | 3/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19706508 | 0.86 | PIK3C3 (0.54) | PIK3C3 | |
| SCHEMBL19699548 | 0.84 | PIK3C3 (0.51) | PIK3C3TYK2MAPTGSK3BEGFR | |
| SCHEMBL16105613 | 0.82 | CSNK1D (0.58) | EGFRABL1NR3C2 | |
| SCHEMBL19699521 | 0.79 | DYRK1A (0.48) | PIK3C3TYK2MAPTGSK3BBUB1 | |
| SCHEMBL19699504 | 0.78 | TYK2 (0.42) | PIK3C3TYK2MAPTGSK3BNPC1 | |
| SCHEMBL19699553 | 0.78 | DYRK1A (0.57) | GSK3BEP300ABL1 | |
| SCHEMBL19699509 | 0.77 | TYK2 (0.43) | PIK3C3TYK2MAPTGSK3BNPC1 | |
| SCHEMBL19699597 | 0.77 | IDH1 (0.49) | TYK2EGFRMAP4K1 | |
| SCHEMBL16105258 | 0.75 | CSNK1D (0.58) | EGFRNR3C2 | |
| SCHEMBL19699566 | 0.74 | MAPT (0.42) | MAPTGSK3BNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | PIK3C3 4720/4885TYK2 2321/4885MAPT 306/4885 |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | PIK3C3 4718/4885TYK2 2258/4885MAPT 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.